Last reviewed · How we verify
Unresectable advanced or recurrent esophageal cancer
Approved treatments
- Yervoy · Bristol-Myers Squibb
Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells. - Yervoy · Bristol-Myers Squibb
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable advanced or recurrent esophageal cancer patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable advanced or recurrent esophageal cancer treatment landscape brief
- Unresectable advanced or recurrent esophageal cancer treatment updates RSS
Frequently asked questions about Unresectable advanced or recurrent esophageal cancer
What drugs treat Unresectable advanced or recurrent esophageal cancer?
Tracked treatments include Yervoy.
What is the treatment for Unresectable advanced or recurrent esophageal cancer?
Standard treatment for Unresectable advanced or recurrent esophageal cancer includes Yervoy. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Unresectable advanced or recurrent esophageal cancer patent cliff · Unresectable advanced or recurrent esophageal cancer CI report
- Treatment: Yervoy · Bristol-Myers Squibb
- Treatment: Yervoy · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing